Genmab A/S (CPH:GMAB)

Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of DKK 126.40 billion. The enterprise value is 105.59 billion.

Market Cap	126.40B
Enterprise Value	105.59B

Important Dates

The last earnings date was Thursday, November 6, 2025.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Genmab has 61.60 million shares outstanding. The number of shares has decreased by -3.12% in one year.

Current Share Class	61.60M
Shares Outstanding	61.60M
Shares Change (YoY)	-3.12%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	1.15%
Owned by Institutions (%)	52.62%
Float	60.85M

Valuation Ratios

The trailing PE ratio is 12.84 and the forward PE ratio is 18.20. Genmab's PEG ratio is 3.61.

PE Ratio	12.84
Forward PE	18.20
PS Ratio	5.16
PB Ratio	3.45
P/TBV Ratio	5.44
P/FCF Ratio	14.95
P/OCF Ratio	14.51
PEG Ratio	3.61

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.13, with an EV/FCF ratio of 12.49.

EV / Earnings	10.48
EV / Sales	4.31
EV / EBITDA	11.13
EV / EBIT	11.70
EV / FCF	12.49

Financial Position

The company has a current ratio of 6.03, with a Debt / Equity ratio of 0.02.

Current Ratio	6.03
Quick Ratio	6.01
Debt / Equity	0.02
Debt / EBITDA	0.10
Debt / FCF	0.11
Interest Coverage	54.85

Financial Efficiency

Return on equity (ROE) is 29.41% and return on invested capital (ROIC) is 16.02%.

Return on Equity (ROE)	29.41%
Return on Assets (ROA)	13.38%
Return on Invested Capital (ROIC)	16.02%
Return on Capital Employed (ROCE)	22.58%
Revenue Per Employee	9.13M
Profits Per Employee	3.76M
Employee Count	2,682
Asset Turnover	0.58
Inventory Turnover	17.23

Taxes

In the past 12 months, Genmab has paid 1.25 billion in taxes.

Income Tax	1.25B
Effective Tax Rate	11.03%

Stock Price Statistics

The stock price has increased by +38.74% in the last 52 weeks. The beta is 0.79, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.79
52-Week Price Change	+38.74%
50-Day Moving Average	1,946.63
200-Day Moving Average	1,567.73
Relative Strength Index (RSI)	63.80
Average Volume (20 Days)	129,675

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of DKK 24.48 billion and earned 10.08 billion in profits. Earnings per share was 159.78.

Revenue	24.48B
Gross Profit	23.10B
Operating Income	9.03B
Pretax Income	11.33B
Net Income	10.08B
EBITDA	9.38B
EBIT	9.03B
Earnings Per Share (EPS)	159.78

Balance Sheet

The company has 21.71 billion in cash and 903.90 million in debt, giving a net cash position of 20.81 billion or 337.81 per share.

Cash & Cash Equivalents	21.71B
Total Debt	903.90M
Net Cash	20.81B
Net Cash Per Share	337.81
Equity (Book Value)	36.61B
Book Value Per Share	594.60
Working Capital	23.74B

Cash Flow

In the last 12 months, operating cash flow was 8.71 billion and capital expenditures -257.02 million, giving a free cash flow of 8.46 billion.

Operating Cash Flow	8.71B
Capital Expenditures	-257.02M
Free Cash Flow	8.46B
FCF Per Share	137.28

Margins

Gross margin is 94.36%, with operating and profit margins of 36.87% and 41.17%.

Gross Margin	94.36%
Operating Margin	36.87%
Pretax Margin	46.28%
Profit Margin	41.17%
EBITDA Margin	38.30%
EBIT Margin	36.87%
FCF Margin	34.54%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.12%
Shareholder Yield	3.12%
Earnings Yield	7.97%
FCF Yield	6.69%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 9.17 and a Piotroski F-Score of 5.

Altman Z-Score	9.17
Piotroski F-Score	5